𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characterization of In vitro immunoselected variants from a highly metastatic murine tumor for alterations in malignant behavior in vivo

✍ Scribed by R. G. Liteplo; P. Frost; T. P. Donaghue; R. S. Kerbel


Publisher
John Wiley and Sons
Year
1984
Tongue
French
Weight
741 KB
Volume
33
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

A new Ly‐6.2^−^ antigen‐loss variant (called L61‐MI) of the highly metastatic DBA/2 mouse (Ly‐6.2^+^) MDAY‐D2 tumor has been obtained by means of a monoclonal anti‐Ly‐6.2 antibody in an in vitro immunoselection technique. Whereas L61‐MI grew poorly when inoculated subcutaneously into the syngeneic host, it grew and metastasized in a similar way to the parental MDAY‐D2 tumor when inoculated into immunosuppressed, athymic nude mice. L61‐MI as well as another Ly‐6.2^−^ variant of the same MDAY‐D2 tumor (called L61) which is poorly metastatic in the syngeneic host salvaged exogenous fucose into glycoproteins and glycolipids at rates 5.5 and 7.8 times that of the parental MDAY‐D2 line. In contrast, the Ly‐6.2^−^ variants exhibited a 50–70% decrease in the incorporation of exogenous mannose into glycoproteins and glycolipids. L61‐MI and L61 also exhibited alterations in the structures of the oligosaccharide moieties linked to the cell surface glycoproteins and/or glycolipids. Thus, the in vitro immunoselection technique can be used to obtain a panel of variants with stable phenotypic alterations in their growth and metastatic capacities. Such mutants may, like previously described lectin‐resistant mutants, be useful in studying the contribution of cell surface glycoproteins and glycolipids to tumorigenicity and metastasis.


📜 SIMILAR VOLUMES


Immunoselection in vitro of a non-metast
✍ Philip Frost; Robert S. Kerbel 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 French ⚖ 438 KB

## Abstract Immunoselection of a non‐metastatic variant of the highly metastatic MDAY‐D2 tumor of DBA/2 mice was achieved by means of an antiserum directed to the LY6.2 surface marker of MDAY‐D2. While the new tumor (MDAY‐D2.L61) expresses no detectable LY6.2, other measurable surface markers inclu